Vaccines 2

• FC 09-01 • Three-year efficacy of the quadrivalent HPV vaccine in a cohort of HIV-positive women See abstract > D. Deborah Money • FC 09-01 • Three-year efficacy of the quadrivalent HPV vaccine in a cohort of HIV-positive women See abstract > D. Deborah Money • FC 09-02 • Impact of baseline covariates on the immunogenicity of 9-valent HPV vaccine in men age 16-26 years See abstract > A. A. LUXEMBOURG • FC 09-03 • Preventing HPV related diseases: an health technology assessment of the nine-valent vaccine in Italy See abstract > C. C. DE WAURE • FC 09-04 • Safety of human papillomavirus 9-valent vaccine: a systematic review and meta-analysis See abstract > A. A.P. COSTA • FC 09-05 • 9-valent vaccine efficacy against related diseases and definitive therapy: comparison to historic placebo population See abstract > A. Anna GIULIANO • FC 09-06 • High vaccine effectiveness against persistent HPV infections up to six years post-vaccination with the bivalent vaccine in a cohort of young Dutch females See abstract > R. R. DONKEN • FC 09-07 • The health economic impact of cross protection due to HPV vaccine See abstract > A. A. SAAH • FC 09-08 • Deconstructing efficacy against high-grade disease irrespective of type of AS04- HPV-16/18 vaccine and HPV - 6/11/16/18 vaccine: a post-hoc analysis from phase III trials See abstract > M. M. RYSER • FC 09-09 • Bivalent vaccine effectiveness against type-specific HPV DNA positivity: evidence for cross-protection against oncogenic types See abstract > P. P. WOESTENBERG